Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
Condition(s):Pyoderma; Pyoderma Gangrenosum; Pyoderma Vegetans; Pyoderma Gangrenosum Surrounding Surgical StomaLast Updated:March 20, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Pyoderma; Pyoderma Gangrenosum; Pyoderma Vegetans; Pyoderma Gangrenosum Surrounding Surgical StomaLast Updated:March 20, 2023Completed
Condition(s):Lymphoma, Non-Hodgkin; Lymphoma, T-CellLast Updated:September 28, 2022Unknown status
Condition(s):Colorectal Cancer; ImmunotherapyLast Updated:July 13, 2023Recruiting
Condition(s):EBV InfectionLast Updated:September 9, 2021Unknown status
Condition(s):Infusion Reaction; Monoclonal AntibodyLast Updated:November 18, 2023Recruiting
Condition(s):Advanced Lung CancerLast Updated:March 26, 2024Recruiting
Condition(s):Colorectal CancerLast Updated:November 9, 2023Not yet recruiting
Condition(s):Metastatic Colorectal CancerLast Updated:January 23, 2018Unknown status
Condition(s):Lymphoepithelioma-Like CarcinomaLast Updated:June 12, 2020Unknown status
Condition(s):Primary Immune Thrombocytopenia (ITP)Last Updated:February 26, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.